Skip to main content
Medical information Clinical review pending

Genetic Testing

MPZ Gene CMT2I Genetic Test

Genetic test using Next-Generation Sequencing (NGS) to detect mutations in the MPZ gene associated with Charcot-Marie-Tooth disease type 2I (CMT2I).

General information only: This page is not a diagnosis or personal medical advice. A qualified clinician should decide whether testing is appropriate and interpret results in context.

Review status: No completed medical review is recorded for this page.

Ask a question
Counselor guidance included Confidential handling Kenya-wide coordination

At a glance

Plan your test

Sample
Blood sample (EDTA tube), extracted DNA, or dried blood spot on an FTA card.
Results
Confirm with the laboratory before booking.
Preparation
No specific patient preparation is required for the blood draw. A detailed clinical history and family history (pedigree chart) are essential for accurate interpretation. Genetic counseling is recommended before testing.
Test priceKSh 40,000

Payment: M-Pesa and card options can be confirmed during booking.

Insurance & government schemes

Is this test covered for you?

We help you verify whether the MPZ Gene CMT2I Genetic Test test can be claimed against your insurer, employer scheme or a Kenyan government health scheme — before you book. Coverage depends on your plan, clinical indication and your provider's rules; final approval always rests with them.

Talk to a claims advisor

Providers & schemes we can help you check

Government & public schemes

SHIF — Social Health Insurance Fund Linda Mama EduAfya NHIF (legacy cards)

Eligibility and benefits follow the current rules of the Social Health Authority (SHA) and applicable government programmes.

Private insurers & employer schemes

Jubilee Health AAR APA Britam CIC Madison Resolution Pioneer Minet Old Mutual GA Life Heritage + other licensed insurers

Names shown for identification only — listing does not imply partnership or guarantee of coverage.

Have these ready when we check

  • Insurer or scheme name & policy / member number
  • A clinician's request / prescription for the test
  • Pre-authorisation letter, if your plan requires one

Free coverage check

Ask us to verify your cover

Send your details and our claims team confirms what documents you need and whether pre-authorisation applies — usually the same working day.

+254

Used only to process your coverage check — see our Privacy Policy. Verification support is free and does not guarantee your provider will pay.

01

Start with fit

Is this the right test for you?

The best test starts with a clear clinical question. These are common reasons a clinician or family may consider this test.

  • ✓Symptoms suggestive of Charcot-Marie-Tooth disease (e.g., muscle weakness, sensory loss).
  • ✓Family history of CMT or related neurological disorders.
  • ✓Confirmation of suspected CMT2I diagnosis.
  • ✓Genetic counseling for individuals with CMT2I or family history.
  • ✓Assessing risk for family members.
02

In plain language

What this test helps you understand

Identifies mutations in the MPZ gene, which are associated with Charcot-Marie-Tooth disease type 2I (CMT2I). This information aids in diagnosis, prognosis, and genetic counseling.
The MPZ Gene CMT2I NGS Genetic DNA Test is a diagnostic tool used to identify genetic variations linked to Charcot-Marie-Tooth disease type 2I (CMT2I). This test utilizes advanced Next-Generation Sequencing (NGS) technology to analyze the MPZ gene. Understanding the genetic basis of neurological disorders like CMT2I is crucial for accurate diagnosis and personalized management. This test provides valuable information for healthcare providers to guide treatment decisions and offer appropriate patient care. It can also be helpful for genetic counseling and family planning. Consult with your doctor to determine if this test is right for you.
03

Medical review status

Clinical review pending

A completed medical review is not recorded for this page. No clinician has endorsed the information shown here. Please discuss testing decisions with a qualified healthcare professional.

Meet the DNA Labs Kenya medical team →
04

A simple process

What happens next?

You do not have to navigate the test alone. We help you move from question to next step.

1

Speak with us

We check the test and answer your questions before collection.

2

Give your sample

Choose home collection or a coordinated hub visit in Kenya. We explain whether this test uses a cheek swab or blood draw.

3

Understand your report

A counselor helps you understand the result and the next steps.

05

Choose your collection

Home collection or a lab visit

We will explain the sample, preparation, and next steps before anything is collected.

Home collection

Choose a coordinated visit at home or another convenient location. Our team confirms the appointment and sample requirements in advance.

Lab or hub visit

Prefer to visit a coordinated location? We can guide you to the right hub and explain what to expect when you arrive.

Ask about locations →
PreparationNo specific patient preparation is required for the blood draw. A detailed clinical history and family history (pedigree chart) are essential for accurate interpretation. Genetic counseling is recommended before testing.
SampleBlood sample (EDTA tube), extracted DNA, or dried blood spot on an FTA card.
MethodologyNext-Generation Sequencing (NGS) targeting the MPZ gene.
PrivacyYour sample and report are handled confidentially. Ask the team how your information is stored and shared.
This test specifically analyzes the MPZ gene. It may not detect mutations in other genes associated with CMT or other neurological conditions. Results should be interpreted in the context of clinical findings and family history. Confirm with the laboratory before booking.
06

Read your report

What common result terms mean

PositiveA finding was identified. Your clinician or counselor will explain what it means for your care.
NegativeThe specific finding tested for was not identified. It does not rule out every possible cause.
VUSA variant was found, but current evidence is not enough to classify it. Your counselor can explain follow-up.
07

Questions people ask

Frequently asked questions

CMT2I is an inherited neurological disorder affecting the peripheral nerves, leading to muscle weakness and sensory loss, primarily in the limbs.
The MPZ gene provides instructions for making a protein essential for the proper function of myelin, the protective sheath around nerve fibers.
Individuals experiencing symptoms of CMT, such as progressive muscle weakness or sensory loss, or those with a family history of the condition, may be candidates for this test.
A healthcare professional, such as a neurologist or genetic counselor, will interpret the results in conjunction with your clinical history and family information.
Yes, genetic counseling before and after testing is highly recommended to understand the implications of the results and discuss family planning.
A blood sample, extracted DNA, or a dried blood spot on an FTA card is required for the test.
08

Collaboration

Open for partnership with hospitals, clinics, doctors & researchers

Whether you are referring patients, building a research programme or supporting students, we work as an extension of your team — with responsive communication and clear scientific standards.

Hospitals & clinics

Referral pathways, coordinated sample logistics and shared reporting that fits your clinical workflow.

Doctors & specialists

LOINC-coded reports, ACMG-based variant classification and a direct scientific line for complex cases.

Research institutions

Sanger sequencing, NGS panels and custom assays — with project design support, batch pricing and agreed turnaround commitments.

Students & academic projects

Discounted laboratory services for college, master's and PhD research projects — including proposal guidance and cost-effective batch testing.

Explore partnerships
09

Trust & transparency

Sources, standards & how this page is maintained

Standards & references

  • ACMG/AMP technical standards for sequence variant interpretation
  • ClinGen curation and gene–disease validity frameworks where applicable
  • LOINC-coded reporting for interoperable results
  • ISO 9001:2015 quality management; ISO 15189 accreditation in progress

Page provenance

  • Last updated: September 27, 2026
  • Medical review: not yet completed
  • Written for patients & clinicians in Kenya; reviewed periodically against current guidance

Medical disclaimer: this page is general information, not a diagnosis or personal medical advice. Testing decisions and result interpretation should be made with a qualified healthcare professional.

Keep exploring

Related tests

View all tests →
Chat on WhatsApp